- Home
- PKBK vs VNDA Comparison
PKBK vs VNDA Comparison
Compare PKBK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKBK
- VNDA
- Stock Information
- Founded
- PKBK 1999
- VNDA 2002
- Country
- PKBK United States
- VNDA United States
- Employees
- PKBK N/A
- VNDA N/A
- Industry
- PKBK Major Banks
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PKBK Finance
- VNDA Health Care
- Exchange
- PKBK Nasdaq
- VNDA Nasdaq
- Market Cap
- PKBK 269.2M
- VNDA 249.4M
- IPO Year
- PKBK N/A
- VNDA 2006
- Fundamental
- Price
- PKBK $20.75
- VNDA $5.33
- Analyst Decision
- PKBK
- VNDA Strong Buy
- Analyst Count
- PKBK 0
- VNDA 2
- Target Price
- PKBK N/A
- VNDA $16.50
- AVG Volume (30 Days)
- PKBK 27.7K
- VNDA 495.7K
- Earning Date
- PKBK 10-21-2025
- VNDA 11-05-2025
- Dividend Yield
- PKBK 3.46%
- VNDA N/A
- EPS Growth
- PKBK 42.58
- VNDA N/A
- EPS
- PKBK 2.56
- VNDA N/A
- Revenue
- PKBK $66,879,999.00
- VNDA $203,467,000.00
- Revenue This Year
- PKBK N/A
- VNDA $15.45
- Revenue Next Year
- PKBK N/A
- VNDA $37.82
- P/E Ratio
- PKBK $8.24
- VNDA N/A
- Revenue Growth
- PKBK 3.52
- VNDA 11.78
- 52 Week Low
- PKBK $16.94
- VNDA $3.81
- 52 Week High
- PKBK $24.29
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- PKBK 32.36
- VNDA 66.70
- Support Level
- PKBK $21.01
- VNDA $4.84
- Resistance Level
- PKBK $21.37
- VNDA $5.48
- Average True Range (ATR)
- PKBK 0.42
- VNDA 0.21
- MACD
- PKBK -0.17
- VNDA 0.07
- Stochastic Oscillator
- PKBK 0.00
- VNDA 86.57
About PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.